Vedanta Biosciences Inc., of Cambridge, Mass., will receive $12 million from Janssen Research & Development LLC, a unit of New Brunswick, N.J.-based Johnson & Johnson, triggered by the start of a phase I trial of VE-202, under the firms' ongoing collaboration.